Ipamorelin vs MK-677

Ipamorelin binds to the ghrelin receptor (GHSR-1a) and stimulates dose-dependent GH release with a clean hormonal profile. Unlike GHRP-6 or hexarelin, it does not significantly stimulate appetite-related pathways or cortisol secretion at standard research doses. This selectivity makes it a frequently studied peptide for protocols where hormonal side-effect profiles are a consideration.

Ipamorelin is a synthetic pentapeptide (Aib-His-D-2-Nal-D-Phe-Lys-NH2) and selective growth hormone secretagogue that acts as a ghrelin receptor (GHS-R1a) agonist, valued in research for its selectivity for GH release with minimal concurrent stimulation of cortisol, prolactin, or ACTH compared to earlier GH-releasing peptides such as GHRP-2 and GHRP-6. Ipamorelin stimulates pulsatile GH secretion from pituitary somatotrophs through ghrelin receptor signaling; its selective endocrine profile was characterized preclinically and distinguishes it from less selective GHRPs, making it a widely used tool compound in GH secretagogue research and the subject of exploratory clinical development for GI motility applications. The only indexed Phase II human trial of ipamorelin examined its effects on postoperative ileus in bowel resection patients, demonstrating GI motility improvements consistent with its enteric GHS-R1a activity; no published human data addresses its effects on GH secretion, body composition, or performance outcomes in the contexts for which it is commonly used as a research compound. Ipamorelin has no FDA approval for any indication; it is a research compound with well-characterized preclinical pharmacology and a single published human trial in a GI context, and claims regarding its use for muscle gain, fat loss, or anti-aging purposes are not supported by published clinical evidence. Ipamorelin is frequently studied in combination with CJC-1295 (a GHRH analogue), with the rationale that CJC-1295 extends the GHRH pulse window while ipamorelin provides selective GHS-R1a stimulation without additional cortisol or prolactin burden. The CJC-1295 ipamorelin combination is among the most commonly researched GH secretagogue pairings in both the research literature and in compounded clinical protocols, and both compounds are available through telehealth providers and compounding pharmacies in the PeptideBase directory. A triple combination of sermorelin, ipamorelin, and CJC-1295 has also been explored in research contexts as a multi-pathway approach to GH axis support, though no published human trial evidence supports this specific combination. Ipamorelin's side effect profile in preclinical and limited clinical research is considered favorable relative to earlier GHRPs. Unlike GHRP-2 and GHRP-6, which produce dose-dependent elevations in cortisol, prolactin, and ACTH, ipamorelin selectively stimulates GH release with minimal effect on these hormones at standard research doses — its selectivity was a primary design objective in its development. Commonly reported observations in research contexts include transient water retention (attributed to IGF-1-mediated sodium reabsorption at higher doses), mild injection-site discomfort, and occasionally headache or flushing shortly after administration, consistent with the acute GH pulse. Long-term use considerations include potential receptor desensitization with continuous daily dosing, which is why cycling protocols (e.g., 5 days on, 2 days off, or monthly off-cycles) are common in research designs. At doses substantially exceeding research norms, GH-class effects such as peripheral paresthesia, joint stiffness, and carpal tunnel-type symptoms have been observed — consistent with GH-excess effects across secretagogue and exogenous HGH literature. Ipamorelin's long-term safety profile in humans has not been established through controlled clinical trials; all available safety observations derive from preclinical studies and the single published Phase II GI motility trial, which was short-duration and not designed to assess endocrine safety endpoints.

MK-677 mimics the action of ghrelin by binding to and activating the GHSR-1a receptor in the pituitary gland, stimulating pulsatile GH release. Its oral bioavailability distinguishes it from peptide-based GH secretagogues and its prolonged half-life results in sustained IGF-1 elevation. Research protocols have explored its effects on lean body mass, bone mineral density, and sleep architecture.

MK-677 (ibutamoren; ibutamoren mesylate) is an orally active, non-peptide small-molecule ghrelin receptor (GHS-R1a) agonist developed by Merck as a research compound for GH deficiency and muscle-wasting conditions, notable as one of the few GH secretagogues with confirmed oral bioavailability and a substantial human clinical dataset spanning multiple Phase 2 randomized controlled trials. MK-677 mimics ghrelin to stimulate pulsatile GH and IGF-1 secretion from the pituitary in a dose-dependent manner without directly replacing GH, and RCTs have demonstrated significant increases in fat-free mass and GH secretion in obese adults and in hemodialysis patients with nutritional deficits, establishing the pharmacology of oral GHS-R1a agonism in humans. Despite robust human pharmacological evidence, MK-677 was not advanced to FDA registration; Merck Phase 3 trials showed efficacy on surrogate endpoints but did not demonstrate the clinical outcomes required for approval, commercial development was discontinued, and no approved indication exists. MK-677 is a non-peptide research compound — not a peptide in the pharmacological sense — with no FDA approval; it is widely available through research chemical suppliers and used off-label, and considerations including its documented effects on insulin sensitivity, fasting glucose, and sustained IGF-1 elevation are relevant to its risk profile. MK-677 dosage: clinical trials studied doses of 10 mg, 25 mg, and 50 mg orally once daily. The most frequently cited research dose in the literature is 25 mg/day for body composition studies; 10 mg/day has been used in elderly populations. Administration before sleep is studied to align the GH pulse with the natural nocturnal GH peak. Unlike injectable GH secretagogues that require reconstitution, MK-677's oral route is a practical distinction — it eliminates the injection preparation process relevant to peptides requiring bacteriostatic water reconstitution. Side effects documented in RCTs include increased appetite (a direct ghrelin-mimetic effect), mild peripheral edema from water retention, and transient increases in fasting blood glucose — a clinically relevant finding for individuals with pre-existing insulin sensitivity concerns. Sustained IGF-1 elevation from long-duration use is a differentiated risk characteristic compared to short-half-life injectable GHRPs. MK-677 is sometimes grouped with performance peptides due to overlapping research contexts but is pharmacologically a non-peptide small molecule. Licensed telehealth and anti-aging providers who carry growth hormone secretagogues are listed in the PeptideBase directory.